Simplyali241

VIMTA Labs LONG after multiyear breakout

看多
NSE:VIMTALABS   VIMTA LABORATORIES
Vimta Labs is engaged in the business of testing food and drugs. It also does contract research for clinical research and pre-clinical studies.
Company was expected to give good quarter and has delivered.

VIMTA LABS: Q2 CONS NET PROFIT 97M RUPEES VS 75M (YOY); 81M (QOQ) || Q2 REVENUE 754M RUPEES VS 593M (YOY); 613M (QOQ)
DII have bought significantly in the last quarter, Some news is coming up
TARGET : See CHART

免責聲明

這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。